New First-Line Combination Therapies in Advanced RCC

EP. 1: Treatment Advances for Frontline mRCC

March 31st 2021

Bradley A. McGregor, MD, of the Dana-Farber Cancer Institute, reacts to the emergence of new treatment gaps associated with novel combination regimens as first-line therapy for patients with metastatic renal cell carcinoma.

EP. 2: Frontline Treatment Approaches for Favorable-Risk mRCC

March 31st 2021

Current treatment approaches that can be used to treat favorable-risk metastatic renal cell carcinoma in the first-line setting and implications for individualizing therapy despite guidance provided by the IMDC criteria.

EP. 3: Favorable-Risk mRCC: Sequencing Therapy

April 7th 2021

Best approaches to sequencing therapy for patients with favorable-risk metastatic renal cell carcinoma following first-line therapy with novel combinations such as ipilimumab and nivolumab.

EP. 4: Favorable-Risk mRCC: Combination Regimens Vs Single-Agent Therapy

April 7th 2021

Factors that oncologists need to consider when deciding whether to initiate single-agent therapy or a novel combination regimen as frontline treatment for patients with favorable-risk metastatic renal cell carcinoma.

EP. 5: Favorable-Risk mRCC: First-Line Treatment Selection

April 14th 2021

Oncologists discuss how they select an appropriate novel combination strategy as first-line therapy for patients with favorable-risk metastatic renal cell carcinoma.

EP. 6: Favorable-Risk mRCC: Aggressive Therapy and Disease Progression

April 14th 2021

The rationale for treating favorable-risk metastatic renal cell carcinoma with early, aggressive therapy and considerations for approaching disease progression.

EP. 7: Frontline Treatment for Intermediate/Poor-Risk mRCC

April 21st 2021

Considerations for evolving from using single-agent therapy to combination approaches to treat intermediate or poor-risk metastatic renal cell carcinoma based on more recent data demonstrated in clinical trials.

EP. 8: Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCC

April 21st 2021

Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.

EP. 9: Novel Strategies for Intermediate-/Poor-Risk mRCC: Optimizing Therapy

April 28th 2021

Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.

EP. 10: The CheckMate 9ER Study in mRCC

April 28th 2021

Takeaways of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib in previously untreated metastatic renal cell carcinoma.

EP. 11: Frontline Therapy for mRCC: Assessing Quality of Life

May 5th 2021

Expert oncologists debate the significance of using quality of life as a metric when assessing patients’ responses to therapy for metastatic renal cell carcinoma.

EP. 12: Frontline Treatment for mRCC: Dose Adjustments/Discontinuation

May 5th 2021

Advice for appropriately dosing newer novel-based strategies used to treat metastatic renal cell carcinoma and best practices to help community oncologists avoid drug discontinuations.

EP. 13: PD-1 Vs PD-L1 Inhibition for Frontline mRCC

May 12th 2021

A panel of oncologists discuss the appropriateness for using PD-1 inhibitors versus PD-L1 inhibitors as frontline treatment for metastatic renal cell carcinoma.

EP. 14: The CLEAR Study in mRCC

May 12th 2021

Robert S. Alter, MD, of the John Theurer Cancer Center, highlights key data revealed by the phase 3 CLEAR study in metastatic renal cell carcinoma.

EP. 15: Lenvatinib Plus Pembrolizumab or Everolimus for mRCC

May 19th 2021

Based on data demonstrated by the recent CLEAR study in metastatic renal cell carcinoma, oncologists comment on decisions for using lenvatinib plus pembrolizumab vs lenvatinib plus everolimus.

EP. 16: Frontline mRCC: I-O/TKI Treatment Regimens

May 19th 2021

Limitations of current data surrounding the appropriate use of immunotherapy plus a tyrosine kinase inhibitor as frontline therapy for patients with metastatic renal cell carcinoma and current recommendations for selecting an appropriate combination regimen.

EP. 17: mRCC Treatment: Novel-Based Approaches on the Horizon

May 26th 2021

An overview of novel-based treatment strategies and biomarkers that are currently under investigation to help address current unknowns when treating patients with metastatic renal cell carcinoma.

EP. 18: Biomarker Development in mRCC

May 26th 2021

The significance of studying predictive biomarkers to help oncologists identify mechanisms of resistance to immunotherapy agents in metastatic renal cell carcinoma prior to initiating therapy.

EP. 19: Second-Line Treatment Approaches for Metastatic RCC

June 2nd 2021

A brief discussion on current second-line treatment options available to patients with metastatic renal cell carcinoma previously treated with a novel-based regimen.

EP. 20: Series Wrap-up: Novel Therapies for mRCC

June 2nd 2021

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.